Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine Plus Rituximab for Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00939328Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of bendamustine, rituximab in chronic lymphocytic leukemia (CLL), sponsored by SWOG Cancer Research Network. Planned start Sep 2009; status: withdrawn.
02
Drugs
bendamustinerituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00939328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939328.